艾美赛珠单抗改善获得性血友病A患者血浆体外凝血潜力
本研究评估双特异性抗体艾美赛珠单抗在获得性血友病A(AHA)患者血浆中的体外凝血效果。组织因子触发凝血酶生成试验显示,艾美赛珠单抗可恢复被抗FVIII抗体抑制的凝血酶生成峰值,且不依赖抑制物表位特异性。在16例AHA患者血浆中,20和100 µg/mL艾美赛珠单抗使凝血酶生成恢复至中位43.9%和92.2%。
要点
- 艾美赛珠单抗可改善AHA患者血浆体外凝血酶生成。
- 凝血酶生成恢复程度随艾美赛珠单抗浓度增加而提高。
- 2型抑制物患者恢复率可能高于1型抑制物患者。
核心结论
- 艾美赛珠单抗可改善获得性血友病A患者血浆的体外凝血潜力。
研究设计与样本
- 使用组织因子触发凝血酶生成试验,在正常血浆预孵育抗FVIII单克隆抗体及16例AHA患者血浆中评估艾美赛珠单抗的体外凝血效果。
主要发现
- 在正常血浆预孵育不同表位抗FVIII单抗的实验中,20 µg/mL艾美赛珠单抗使降低的凝血酶生成峰值恢复至46%至72%。
- 在16例AHA患者血浆中,艾美赛珠单抗使所有病例的凝血酶生成峰值增加,且不依赖抑制物表位特异性。
- 20和100 µg/mL艾美赛珠单抗使凝血酶生成分别恢复至中位43.9%和92.2%。
- 部分病例间存在差异,2型抑制物患者恢复率可能高于1型抑制物患者。
临床怎么用
- 艾美赛珠单抗可能作为AHA患者尤其是急性严重出血需旁路治疗时的潜在治疗选择。
局限性
- 研究为体外实验,样本量有限(n=16),结果需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acquired hemophilia A (AHA) is caused by autoantibodies against factor (F)VIII, and is characterized by severe, spontaneous bleeding, which can be life-threatening. Emicizumab, an anti-FIXa/FX bispecific antibody, significantly reduces bleeding events in congenital hemophilia A (HA) with and without inhibitors. The known pathophysiological mechanisms and current preclinical data in HA suggest that emicizumab could provide effective treatment for AHA, but the coagulation activities of emicizumab in these patients remain unknown. AIM: To evaluate the coagulant effects of emicizumab in plasma from AHA patients. METHODS AND RESULTS: Tissue factor-triggered thrombin generation assays using normal plasma preincubated with anti-FVIII monoclonal antibodies recognizing different epitopes demonstrated that 20 µg/mL emicizumab recovered the depressed peak levels of thrombin generation to 46% to 72%. Further studies were devised, therefore, to simulate the clinical course in AHA patients, including during the acute phase for severe bleeding requiring FVIII-bypassing therapy, and during the subacute/chronic phase with less bleeding. Various concentrations of emicizumab were used to represent the potential changes in plasma levels based on the half-life of the antibody (~30 days). The ex vivo addition of emicizumab to plasma samples from AHA patients (n = 16) increased peak thrombin in all cases, irrespective of the inhibitor epitope specificity. Thrombin generation at 20 and 100 µg/mL emicizumab was restored to (median) 43.9% and 92.2%, respectively. Differences were evident in some cases, however, and recovery rates appeared likely to be greater in patients with type 2 inhibitor than those with type 1. CONCLUSION: Emicizumab improved ex vivo coagulation potential in plasma from AHA patients.
引用
- Takeyama M, Nogami K, Matsumoto T, et al. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost. 2020. PMID: 31984625. doi:10.1111/jth.14746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。